GVR Report cover Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Dementia, Bipolar & Unipolar Depression) & Segment Forecasts, 2018 - 2025Report

Antipsychotic Drugs Market By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application (Schizophrenia, Dementia, Bipolar & Unipolar Depression) & Segment Forecasts, 2018 - 2025

  • Published Date: Feb, 2017
  • Base Year for Estimate: 2016
  • Report ID: GVR-1-68038-408-6
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 90

Industry Insights

The global antipsychotic drugs market size was valued at USD 11.7 billion in 2015 and is expected to grow at a CAGR of 2.1% over the forecast period. Growing prevalence of psychosis and related diseases is driving the demand for antipsychotic drugs. The major factors contributing towards the growing incidence of these disorders include genetic mutations, substance-induced psychoses, and physical illness resulting in depression.

The introduction of newer antipsychotic compounds and huge investments for R&D are boosting the market growth. In addition, increasing efforts taken by the market players to expand therapeutic applications of these medicines are anticipated to create opportunities for the expansion of portfolio of antipsychotics in the near future, thereby fueling the demand.

Japan antipsychotic drugs market, by drug class type, 2014 - 2025 (USD Million)

Japan antipsychotic drugs market

Adverse effects such as insomnia, dry mouth, drowsiness, blurred vision, and probability of habit formation may have a harmful impact on a patient’s health. These effects are challenging the adoption of these drugs.

The patent expirations of key brands, such as Seroquel, Risperdal, Zyprexa, and Invega are restraining the growth of these brands. Moreover, players are introducing generic versions of antipsychotics and have begun investigating new therapeutic applications for these products; hence the generic products are slowly replacing the established brands in antipsychotic market.

Drug Class Insights

The antipsychotics are segmented into three classes: first generation, second generation, and third generation. The typical or standard antipsychotics were first-generation antipsychotic drugs developed in 1950s. However, drugs under this category pose risks such as blurred vision and drowsiness and some may have fatal effects. Thus, these products are expected to witness a negative growth over the forecast period, with availability of relatively more effective drugs with fewer adverse effects.

The second generation holds the largest share in the market. This class named as atypical antipsychotics includes clozapine, risperidone, sertindole, asenapne, olanzapine, paliperidone, quetiapine. These are used for treatment of schizophrenia and have quickly begun replacing the older, first-generation antipsychotics.

The third generation, aripiprazole (Abilify) is indicated for the treatment of schizophrenia and is also used as maintenance therapy for this disease. The clinical advantages of safety and tolerability of aripiprazole contribute to the segment’s growth. Thus, it is expected to be the fastest growing segment with a CAGR of over 2.4% in the forecast period. 

Application Insights

The antipsychotics are used in treating schizophrenia, different types of bipolar disorders, major depression (unipolar), dementia, and other psychotic disorders. These products have first-line therapeutic applications during treatment and maintenance phases of schizophrenia. The etiology of schizophrenia is still unknown; thus the treatment primarily aims at eliminating the symptoms of the disease. Application of antipsychotics in treating schizophrenia accounts for the largest revenue share.

Furthermore, there is growing detection of unipolar disorder, which is a type of major depression, since the past decade owing to rising awareness regarding the disorder and available treatments. Thus, this segment is anticipated to grow at the fastest rate.

Regional Insights

North America dominated the market by capturing the largest revenue share in 2015. According to the Anxiety and Depression Association of America, about 6.7% of the U.S. population aged 18 years and above was suffering from major depression in 2016. Many people with physical illnesses suffer from co-occurring disorders. Increasing prevalence of mental health disorders, such as schizophrenia and bipolar disorder, is driving the antipsychotics demand in North America.

Asia Pacific is expected to exhibit the fastest growth in the near future due to rising social awareness regarding psychotic disorders and other associated disorders, such as bipolar (mania), anxiety, and major depression. Also, growing access and availability of medicines for treatment and management of the symptoms of mental illnesses is expected to drive the growth of the Asia Pacific market.

Global antipsychotic drugs market, by application, 2015 (USD Million)

Global antipsychotic drugs market

Competitive Insights

Some of the major players competing in this market include, but are not limited to, Johnson & Johnson; Pfizer, Inc.; Eli Lilly & Co.; Bristol-Myers Squibb. These companies hold a strong position globally mainly due to few commercially available antipsychotic drugs with a strong brand image.

Some other players are AstraZeneca; Glaxo SmithKline, Plc; and Allergan, Inc. Competition in the market is expected to intensify in the near future since several companies are now focusing on development of newer and better antipsychotics with lesser or negligible adverse effects to gain competitive advantage over others.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America& MEA

Country scope

U.S., Canada, UK, Germany, China, Japan, Brazil, Mexico, & South Africa

Report coverage

Revenue, company share, competitive landscape, growth factors, trends

15% free customization scope (equivalent to 5 analysts working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the antipsychotic drugs market on the basis of drug classes, application, and region:

  • Drug Class Outlook (Revenue, USD Million; 2014 - 2025)

    • First Generation

    • Second Generation

    • Third Generation

  • Application Outlook (Revenue, USD Million; 2014 - 2025)

    • Schizophrenia

    • Bipolar disorder

    • Unipolar depression

    • Dementia

    • Others

  • Regional Outlook (Revenue, USD Million; 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Mexico

      • Brazil

    • MEA

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.